NONALCOHOLIC FATTY LIVER DISEASE - SOME ASPECTS OF PREVENTION
Keywords:
nonalcoholic fatty liver disease, prevention, hepatic steatosis, fatty dystrophy, metabolic syndrome, multimodal processAbstract
Nowadays, NAFLD is considered one of the leading causes of chronic liver diseases globally. This is probably because a patient with NAFLD usually had more severe diseases - diabetes mellitus type 2 (DM-2), metabolic syndrome, etc. On the one hand, after it was established that insulin resistance underlies these metabolic diseases and, on the other hand, that compensation for these conditions does not eliminate NAFLD, and the presence of NAFLD worsens the course of the underlying disease, interest in its study increased significantly. The development of NAFLD is increasingly associated with the hypothesis of multifactorial parallel effects, or "multiple parallel hits" ("multiple parallel hits"). According to this hypothesis, the pathogenesis of NAFLD appears to be a model that generalizes the interaction of such complex factors as BP, FWS formation, adipocytokines and the gut microbiota, which is involved in the regulation of metabolism, systemic inflammation, BP, highlighting the role of the immune system in metabolic inflammation in NAFLD. Given the disease's pathogenesis, hypolipidemic agents from the group of fibrates can be effective in patients with NAFLD. NAFLD treatment's general goals should be to improve patient's quality of life, reduce hepatic and cardiovascular morbidity and mortality, prevent the development and progression of concomitant pathology of the digestive organs. Modern therapeutic tactics presuppose lifestyle modification and medication.
References
Rinella M.E. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015. 313 (22): 2263–73.
Chalasani N, Younossi Z, Lavine JE, et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenter ology. Gastroenterology. 2012. 142 (7): 1592– 1609.
Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. Journal of Hepatology. 2015. 62 (1 Suppl): pp.65–75.
Feldstein AE et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalhocolic fatty liver disease. Hepatology 2006; 44; 27–33.
Hamaguchi M, Koima T, Takeda N et al. The metabolic syndromas a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 772-8.
Donnelly KL, Smith CI, Schwarzenberg SJ et al. Sources of fatty acids stored in the liver and secreted via lipoproteins in patients with non– alcoholic fatty liver disease. J. Clin. Invest. 2005; 115(5):1343–51.
Pimanov S. I. I. American guidelines for diagnosis and treatment of nonalcoholic fatty liver disease: something becomes clear / S.I. Pimanov // Consilium medicum. Gastroenterology. 2012. № 2.pp.92-96.
Polunina T.E. Nonalcoholic liver steatosis in the practice of internist / T.E. Polunina, I.V. Maev // Effective pharmacotherapy in gastroenterology. 2009. № 1. pp. 14-19.
Polunina T.E. Nonalcoholic fatty liver disease. Algorithm of diagnostics and therapeutic tactics. Tutorial. Moscow: Media Medica, 2014. 32 p.
Lazebnik L.B. Metabolic syndrome and digestive organs / L.B. Lazebnik, L.A. Zvenigorodskaya. М., 2009. P.182.
Ivashkin V.T. Clinical variants of metabolic syndrome / V.T. Ivashkin, O.M. Drapkina, O.N. Korneeva. Moscow: MedInform Agency, 2011. 220 p.
Drapkina O.M. Pathogenesis, treatment and epidemiology of NAFLD - what's new? Epidemiology in Russia / O.M. Drapkina, V.I. Smirin, V.T. Ivashkin // RMJ. 2011. № 28. p. 1717.
Diagnostics and treatment of nonalcoholic fatty liver disease. Methodical Recommendations (ed. Prof. V.T. Ivashkin, Acad. of RAS). M.: ROPIP, 2015.
Myazin R.G. Non-alcoholic fatty liver disease: new therapy options. Medical Council, 2014, 13. С. 18–20.
Myazin R.G. Sodium hypochlorite in the treatment of patients with chronic diffuse liver disease. Dissertation of Candidate of Medical Sciences. Volgograd: Volgograd State Medical University, 2006.
Ivashkin V.T., Maevskaya M.V. Lipotoxicity and other metabolic disorders in obesity. Rus. journal gastroenterol. gepatol. coloproctol. 2010; 1: 4–13.
Day CP, Anstee QM, Targher G. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 2013. 10. 330–44.
Spalding KL, Arner E, Westermark PO. Dynamics of fat cell turnover in humans Nature. 2008. 453(7196), 5. 783–7.
Galimova S.F. Drug-induced liver lesions (part 1). . Rus. journal gastroenterol. gepatol. coloproctol. 2012; 22(3): 38–48.
Mc Cullough AJ. The epidemiology and risk factors of NASH Hepatology. 2013. 58, 5. 1644–54.
Ivashkin V.T. Diseases of the liver and biliary tract. M-Vesti, 2005. 536 p.
Mamedov M.N. Guidelines for diagnosis and treatment of metabolic syndrome / M.N. Mamedov. M.: Multiprint, 2005. 24 p.
Ikura Y. Transitions of histopathologic criteria for diagnosing nonalcoholic fatty liver disease during the last three decades World J. Hepatol. 2014. 12, 6. 894–900.
Cohen L. H. Equallypotent inhibitors of cholesterol synthesis in human hepatocytes have distinquishable effects on different cytochrome P 450 enzymes / L. H. Cohen, R. E. van Leeuwen, G. C. van Thiel // Biopharm. Drug Dispos. 2000. Vol. 21. P. 353-364.
De Denus S. Statins and liver toxicity: a meta-analysis / S. de Denus, S. A. Spinier, K. Miller // Pharmactiherapy. 2004. Vol. 24, № 5. P. 584-591.
Kalhan SC, Edmison J, Marczewski S, Dasarathy S, Gruca LL, Bennett C, Duenas C, Lopez R. Methionine and protein metabolism nonalcoholic steatohepatitis: evidence for the lower rate of transmethylation of methionine. ClinSci (Lond). 2011. 121, 4. 179–89.
Zun Xiang, Yi-peng Chen, Kui-fen Ma, Yue-fang Ye, Lin Zheng, Yi-da Yang, You-ming Li, Xi Jin. The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review BMC Gastroenterol. 2013. 13. 140.
Vyuchnova E.S., Maev I.V., Babina S.M. Efficiency of essential phospholipids in the treatment of patients with nonalcoholic steatohepatitis. Clinical perspectives of gastroenterology. 2010. 3. С. 3–11.
Feher J, Vali A, Blazovics A, Lengyel G. The Beneficial Effect of Metadoxine (Pyridoxinepyrrolidone-carboxylate) in the Treatment of Fatty Liver Diseases J. Intern. Med. Res. 2003. 31. 537–51.
Ming LJ, Yin AC. Therapeutic effects of glycyrrhizic acid Nat Prod Commun. 2013. 8, 3. 415–18.
Ka SO, Kim KA, Kwon KD. Silibinin attenuates adipogenesis in 3T3-L1 preadipocytes through a potential upregulation of the insig pathway Int. J. Mol. Med. 2009. 23, 5. 633–37.
Nesina I.A., Lyutkevich A.A. Gepagard Aktiv: evaluation of effectiveness in the risk group to develop the nonalcoholic fatty liver disease. Effective pharmacotherapy. Gastroenterology. 2 (16). 2015.
